Morgan Stanley Ardelyx, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Ardelyx, Inc. stock. As of the latest transaction made, Morgan Stanley holds 3,206,338 shares of ARDX stock, worth $12.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,206,338

Previous 2,421,698 32.4%

Holding current value

$12.8 Million

Previous $12.5 Million 25.74%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$4.91 - $6.36 $3.85 Million - $4.99 Million	784,640 Added 32.4%	3,206,338 $15.7 Million
Q4 2024 Feb 14, 2025	SELL	$4.49 - $6.85 $3.2 Million - $4.88 Million	-712,788 Reduced 22.74%	2,421,698 $12.5 Million
Q3 2024 May 14, 2025	BUY	$5.28 - $7.57 $467,966 - $670,929	88,630 Added 2.91%	3,134,486 $21.6 Million
Q3 2024 Nov 14, 2024	BUY	$5.28 - $7.57 $467,966 - $670,929	88,630 Added 2.91%	3,134,486 $21.6 Million
Q2 2024 May 14, 2025	BUY	$5.89 - $9.31 $3.68 Million - $5.81 Million	624,158 Added 25.77%	3,045,856 $22.6 Million
Q2 2024 Oct 17, 2024	BUY	$5.89 - $9.31 $3.75 Million - $5.93 Million	637,146 Added 26.45%	3,045,856 $22.6 Million
Q2 2024 Aug 14, 2024	BUY	$5.89 - $9.31 $3.75 Million - $5.93 Million	637,146 Added 26.45%	3,045,856 $22.6 Million
Q1 2024 Oct 17, 2024	SELL	$6.05 - $9.74 $3.85 Million - $6.21 Million	-637,146 Reduced 20.92%	2,408,710 $17.6 Million
Q1 2024 Aug 16, 2024	SELL	$6.05 - $9.74 $4.82 Million - $7.76 Million	-796,398 Reduced 24.85%	2,408,710 $17.6 Million
Q1 2024 May 15, 2024	SELL	$6.05 - $9.74 $4.82 Million - $7.76 Million	-796,398 Reduced 24.85%	2,408,710 $17.6 Million
Q4 2023 Aug 16, 2024	BUY	$3.29 - $6.64 $523,939 - $1.06 Million	159,252 Added 5.23%	3,205,108 $19.9 Million
Q4 2023 Feb 13, 2024	BUY	$3.29 - $6.64 $224,460 - $453,014	68,225 Added 2.17%	3,205,108 $19.9 Million
Q3 2023 Nov 15, 2023	BUY	$3.3 - $4.83 $5.61 Million - $8.21 Million	1,699,182 Added 118.19%	3,136,883 $12.8 Million
Q2 2023 Aug 14, 2023	SELL	$3.23 - $4.95 $336,817 - $516,176	-104,278 Reduced 6.76%	1,437,701 $4.87 Million
Q1 2023 May 15, 2023	BUY	$2.68 - $4.79 $363,743 - $650,122	135,725 Added 9.65%	1,541,979 $7.39 Million
Q4 2022 Feb 14, 2023	BUY	$1.22 - $2.85 $872,053 - $2.04 Million	714,798 Added 103.38%	1,406,254 $4.01 Million
Q3 2022 Nov 14, 2022	BUY	$0.59 - $1.44 $173,480 - $423,408	294,034 Added 73.99%	691,456 $823,000
Q2 2022 Oct 27, 2022	BUY	$0.51 - $1.17 $57,297 - $131,448	112,349 Added 39.41%	397,422 $235,000
Q2 2022 Aug 15, 2022	BUY	$0.51 - $1.17 $57,297 - $131,448	112,349 Added 39.41%	397,422 $235,000
Q1 2022 Oct 27, 2022	SELL	$0.65 - $1.18 $73,026 - $132,571	-112,349 Reduced 28.27%	285,073 $304,000
Q1 2022 May 13, 2022	SELL	$0.65 - $1.18 $1 Million - $1.82 Million	-1,544,775 Reduced 84.42%	285,073 $304,000
Q4 2021 Feb 14, 2022	SELL	$0.86 - $1.7 $387,150 - $765,297	-450,175 Reduced 19.74%	1,829,848 $2.01 Million
Q3 2021 Nov 15, 2021	BUY	$1.27 - $8.17 $2.9 Million - $18.6 Million	2,280,023 New	2,280,023 $3.01 Million

Others Institutions Holding ARDX

# of Institutions

235

Shares Held

166M

Call Options Held

490K

Put Options Held

2.35M

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $615M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account